SFX by Ex Libris Inc.

Title:	Genomic impact of transient low-dose decitabine treatment on primary AML cells
Source:	Blood [0006-4971] Klco, Jeffery yr:2013

Basic

Sorry, no full text available...

Please use the document delivery service (see below)

Holding information

Holdings in library search engine ALBERT

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Wunderlich, M. "AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model." Blood 121.12 (2013): 90-7.
description	2.	Fujikane, T. "Genomic screening for genes upregulated by demethylation revealed novel targets of epigenetic silencing in breast cancer." Breast Cancer Research and Treatment 122.3 (2010): 699-710.
description	3.	Vo, T. "Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML." Cell 151.2 (2012): 344-355.
description	4.	Wang, L. "Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responses." PLoS ONE 8.5 (2013).
description	5.	Rahmani, M. "Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism." Cancer research (2012): 1340-1351.
description	6.	Sexauer, A. "Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML." Blood 120.20 (2012): 4205-4214.
description	7.	Jan, M. "Clonal evolution of acute leukemia genomes." Oncogene 32.2 (2012): 135-140.
description	8.	Tang, Y. "Autophagy induction of Acute Myeloid Leukemia (AML) cells after treatment with low dose-cytarabine (Ara-C) and enhanced cytocidal effect on AML cells by combined treatment with ara-c plus lenograstim." Blood 110.11 (2007): 114-114.
description	9.	Yamamoto, M. "Epigenetic alteration of the NF-κB-inducing kinase (NIK) gene is involved in enhanced NIK expression in basal-like breast cancer." Cancer science 101.11 (2010): 2391-2397.
description	10.	Liu, M. "The role of microRNAs in colorectal cancer." Journal of Genetics and Genomics 37.6 (2010): 347-358.
description	11.	Sigalotti, L. "Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies." Journal of Translational Medicine 8.1 (2010): 56-56.
description	12.	Lange, Robert C. "What an epigenome remembers." BioEssays 32.8 (2010): 659-668.
description	13.	Nelson, V. "Transgenerational genetic effects." Epigenomics 2.6 (2010): 797-806.
description	14.	Bell Horwath, Tiffany R. "Novel ROS-activated agents utilize a tethered amine to selectively target acute myeloid leukemia." Bioorganic and medicinal chemistry letters 23.10 (2013): 2951-2954.
description	15.	Meynet, O. "Glycolysis inhibition targets Mcl-1 to restore sensitivity of lymphoma cells to ABT-737-induced apoptosis." Leukemia 26.5 (2011): 1145-1147.
description	16.	Broxmeyer, Hal E. "A ROSy future for metabolic regulation of HSC division." Nature medicine 18.9 (2012): 1334-6.
description	17.	Macias Perez, Ines M. "GS-1101: a delta-specific PI3K inhibitor in chronic lymphocytic leukemia." Current Hematologic Malignancy Reports 8.1 (2013): 22-27.
description	18.	Altman, Jessica K. "Inhibition of Mnk kinase activity by cercosporamide and suppressive effects on acute myeloid leukemia precursors." Blood 121.18 (2013): 3675-81.
description	19.	Clouser, Christine L. "Anti-HIV-1 activity of resveratrol derivatives and synergistic inhibition of HIV-1 by the combination of resveratrol and decitabine." Bioorganic and medicinal chemistry letters 22.21 (2012): 6642-6646.
description	20.	Eleni D. Lagadinou, Eleni D. "BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells." Cell stem cell 12.3 (2013): 329-341.